Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

Mycoses

Volumn 60, Issue 8, 2017, Pages 493-507

  Kyriakidis, Ioannis ^a   Tragiannidis, Athanasios ^a   Zündorf, Ilse ^b   Groll, Andreas H ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

alemtuzumab; basiliximab; daclizumab; monoclonal antibodies; Pneumocystis; rituximab

Indexed keywords

ABATACEPT; ALEMTUZUMAB; BELATACEPT; CD20 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; LYMPHOCYTOPENIA; MACROMOLECULE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC MYCOSIS; T LYMPHOCYTE; CHILD; CLASSIFICATION;

ANTIBODIES, MONOCLONAL; CHILD; HUMANS; IMMUNOLOGIC FACTORS; INVASIVE FUNGAL INFECTIONS;

EID: 85018256865     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12621     Document Type: Review

References (231)

1. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009;22:274-290.
2. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, Gershwin ME. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev. 2009;9:67-81.
3. Arnold TM, Sears CR, Hage CA. Invasive fungal infections in the era of biologics. Clin Chest Med. 2009;30:279-286.
4. Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol. 2009;26:175-183.
5. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
6. McCluggage LK. Safety of TNF inhibitors in adolescents and children. Adolesc Health Med Ther. 2010;2:1-8.
7. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99.
8. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am. 2011;25:117-138.
9. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am. 2010;24:285-306.
10. Jain A, Singh JA. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013;5:265-299.
11. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol. 2005;129:569-582.
12. Martin A, Tisch RM, Getts DR. Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy. Clin Immunol. 2013;148:136-147.
13. Chatenoud L, Waldmann H. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. Rev Diabet Stud. 2012;9:372-381.
14. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev. 2014;6:CD010253.
15. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81:953-965.
16. Agüero J, Almenar L, Martinez-Dolz L, et al. Variations in the frequency and type of infections in heart transplantation according to the immunosuppression regimen. Transplant Proc. 2006;38:2558-2559.
17. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001;20:1282-1290.
18. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10:86-124.
19. Kahana L, Narvarte J, Ackermann J, et al. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial. Am J Kidney Dis. 1989;14:5-9.
20. Kim PT, Chinnakotla S, Davis G, et al. Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. Proc (Bayl Univ Med Cent). 2011;24:287-294.
21. Whiting JF, Rossi SJ, Hanto DW. Infectious complications after OKT3 induction in liver transplantation. Liver Transpl Surg. 1997;3:563-570.
22. Rabin AS, Givertz MM, Couper GS, et al. Risk factors for invasive fungal disease in heart transplant recipients. J Heart Lung Transplant. 2015;34:227-232.
23. Knop S, Hebart H, Gratwohl A, et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia. 2007;21:1830-1833.
24. Gajarski RJ, Blume ED, Urschel S, et al. Infection and malignancy after pediatric heart transplantation: the role of induction therapy. J Heart Lung Transplant. 2011;30:299-308.
25. Orencia. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000701/WC500048935.pdf. Accessed October 28, 2016.
26. Nulojix. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002098/WC500108355.pdf. Accessed October 28, 2016.
27. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;4:CD007277.
28. Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
29. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
30. Karino T, Osaki K, Kanamori K, Yahata T. Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48:980-984.
31. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228-234.
32. Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62:821-825.
33. Neff K, Stack J, Harney S, Henry M. The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis. Thorax. 2010;65:545-546.
34. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25-32.
35. Ospina FE, Agualimpia A, Bonilla-Abadía F, Cañas CA, Tobón GJ. Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with abatacept. Case Rep Rheumatol. 2014;2014:835050.
36. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51:2120-2130.
37. Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875-2883.
38. Charpentier B, Medina Pestana JO, Del C, Rial M, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2013;13:2884-2891.
39. Haidinger M, Hecking M, Memarsadeghi M, et al. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept. Transpl Infect Dis. 2009;11:171-174.
40. Kasper EM, Bartek J Jr, Johnson S, Kasper BS, Pavlakis M, Wong M. Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression. Surg Neurol Int. 2011;2:75.
41. Yervoy. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf. Accessed October 28, 2016.
42. Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause Pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology. 2015;4:e1040218.
43. Simulect. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000207/WC500053543.pdf. Accessed October 28, 2016.
44. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;1:CD003897.
45. Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA. Antibody induction therapy for lung transplant recipients. Cochrane Database Syst Rev. 2013;11:CD008927.
46. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database Syst Rev. 2014;5:CD010252.
47. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant. 2006;6:1913-1921.
48. Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev. 2013;12:CD008842.
49. Maschmeyer G, Patterson TF. New immunosuppressive agents and risk for invasive fungal infections. Curr Infect Dis Rep. 2009;11:435-438.
50. Zanfi C, Lauro A, Cescon M, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc. 2010;42:35-38.
51. Kovac D, Kotnik V, Kandus A. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients. Transplant Proc. 2005;37:4230-4234.
52. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol. 2004;124:777-786.
53. Safdar N, Smith J, Knasinski V, et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis. 2010;66:7-15.
54. Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684-1690.
55. Primeggia J, Matsumoto CS, Fishbein TM, Karacki PS, Fredette TM, Timpone JG. Infection among adult small bowel and multivisceral transplant recipients in the 30-day postoperative period. Transpl Infect Dis. 2013;15:441-448.
56. Nishida S, Levi D, Kato T, et al. Ninety-five cases of intestinal transplantation at the University of Miami. J Gastrointest Surg. 2002;6:233-239.
57. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705-2713.
58. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879-886.
59. Bech B, Pressler T, Iversen M, et al. Long-term outcome of lung transplantation for cystic fibrosis–Danish results. Eur J Cardiothorac Surg. 2004;26:1180-1186.
60. Wang JZ, Liu KY, Xu LP, et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc. 2011;43:1928-1933.
61. Perales MA, Ishill N, Lomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant. 2007;40:481-486.
62. Labbé AC, Su SH, Laverdière M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2007;13:1192-1200.
63. Hou CY, Xu LL, Chen H, et al. Intestinal aGVHD and infection after hematopoietic stem cell transplantation. Med Sci Monit. 2013;19:802-806.
64. Florescu DF, Islam KM, Grant W, et al. Incidence and outcome of fungal infections in pediatric small bowel transplant recipients. Transpl Infect Dis. 2010;12:497-504.
65. Yuksekkaya HA, Arikan C, Tumgor G, Aksoylar S, Kilic M, Aydogdu S. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis. Pediatr Transplant. 2011;15:E105-E109.
66. Delucchi BA, Valenzuela AM, Ferrario BM, et al. Early steroid withdrawal in pediatric renal transplantation. Rev Med Chil. 2006;134:1393-1401.
67. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol. 2003;74:119-124.
68. Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol. 2009;31:456-461.
69. Lemtrada. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf. Accessed October 28, 2016.
70. Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014;59:S360-S364.
71. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
72. Skoetz N, Bauer K, Elter T, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev. 2012;2:CD008078.
73. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16-24.
74. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation. 2006;81:17-20.
75. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol. 2009;88:121-132.
76. Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012;4:e2012070.
77. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23:145-153.
78. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009;9:365-370.
79. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151-153.
80. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
81. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024-7031.
82. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
83. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010;28:4500-4506.
84. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093-1101.
85. Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107:1724-1730.
86. Kim SJ, Moon JH, Kim H, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012;53:1515-1524.
87. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132:3-12.
88. Buckstein R, Fraser G, Cheung M, et al. Alemtuzumab and CHOP chemotherapy for the treatment of aggressive histology peripheral T cell lymphomas: a multi-center phase I study. Clin Lymphoma Myeloma Leuk. 2016;16:18-28.e4.
89. Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645-2651.
90. Blennow O, Remberger M, Klingspor L, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45:1710-1718.
91. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis. 2008;10:162-167.
92. Malladi RK, Peniket AJ, Littlewood TJ, et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant. 2009;43:709-715.
93. Bolaños-Meade J, Luznik L, Muth M, et al. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009;43:477-480.
94. Novitzky N, Rouskova A. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy. 2001;3:165-173.
95. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44:204-212.
96. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002-1011.
97. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis. 2007;9:22-27.
98. Silveira FP, Marcos A, Kwak EJ, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect. 2006;53:241-247.
99. Walsh R, Ortiz J, Foster P, Palma-Vargas J, Rosenblatt S, Wright F. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis. 2008;10:236-239.
100. Yuan-Xin L, Ning L, You-Sheng L, et al. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. Transplant Proc. 2010;42:29-34.
101. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation. 2003;75:1512-1517.
102. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc. 2005;37:934-936.
103. Muthusamy AS, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am J Transplant. 2008;8:2126-2131.
104. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772-786.
105. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10:382-388.
106. van Loenhout KC, Groves SC, Galazka M, et al. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg. 2010;10:190-194.
107. Roux C, Thyss A, Gari-Toussaint M. Prostatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia. J Mycol Med. 2013;23:270-273.
108. Karia S, Jeyapalan K, Kennedy B. Aspergillus fumigatus osteomyelitis in a patient receiving alemtuzumab for B-cell chronic lymphocytic leukaemia. Br J Haematol. 2011;153:147.
109. Henn A, Mellon G, Benoît H, et al. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia. Scand J Infect Dis. 2014;46:231-234.
110. Anoop P, Stanford M, Saso R, Dearden CE. Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia. J Infect Chemother. 2010;16:150-151.
111. Bassetti M, Repetto E, Mikulska M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother. 2009;21:211-214.
112. Dilhuydy MS, Jouary T, Demeaux H, Ravaud A. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. Br J Haematol. 2007;137:490.
113. Hotz C, Ingen-Housz-Oro S, Tran Van Nhieu J, et al. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab. Eur J Dermatol. 2011;21:1018-1020.
114. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44:e115-e117.
115. Otahbachi M, Nugent K, Buscemi D. Granulomatous Pneumocystis jiroveci pneumonia in a patient with chronic lymphocytic leukemia: a literature review and hypothesis on pathogenesis. Am J Med Sci. 2007;333:131-135.
116. Gerard LM, Xing K, Sherifi I, et al. Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. Int J Hematol. 2012;95:445-450.
117. Nieto-Ríos JF, Serna-Higuita LM, Guzman-Luna CE, et al. Histoplasmosis in renal transplant patients in an endemic area at a reference hospital in Medellin. Colombia. Transplant Proc. 2014;46:3004-3009.
118. Liu JY, Chen WT, Ko BS, et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol. 2011;49:872-878.
119. Jamet D, Quinio D, Moalic E, et al. Systemic microsporidiosis and toxoplasmosis in a patient with T prolymphocytic leukemia. Med Mal Infect. 2009;39:406-408.
120. Chu D, Stevens M, Gladstone DE. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int. 2007;27:1173-1175.
121. Khandelwal P, Lawrence J, Filipovich AH, et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Pediatr Transplant. 2014;18:94-102.
122. Shah AJ, Kapoor N, Crooks GM, et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant. 2007;13:584-593.
123. Elebute MO, Ball SE, Gordon-Smith EC, Sage D, Marsh JC. Autologous recovery following non-myeloablative unrelated donor bone marrow transplantation for severe aplastic anaemia. Ann Hematol. 2002;81:378-381.
124. MabThera. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed October 28, 2016.
125. Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169.
126. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15:e2-e16.
127. Alvarez B, Arcos J, Fernández-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr Opin Pulm Med. 2011;17:172-179.
128. Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144:258-265.
129. Jiang X, Mei X, Feng D, Wang X. Prophylaxis and treatment of Pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One. 2015;10:e0122171.
130. Lin PC, Hsiao LT, Poh SB, et al. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol. 2007;86:95-100.
131. Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139-140.
132. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010;51:797-801.
133. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol. 2008;80:275-276.
134. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538-1543.
135. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496-502.
136. Nissen JC, Hummel M, Brade J, et al. The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage—a single center experience. BMC Infect Dis. 2014;14:364.
137. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol. 2008;87:393-397.
138. Lim KH, Yoon HI, Kang YA, et al. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med. 2010;25:86-92.
139. Katsuya H, Suzumiya J, Sasaki H, et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50:1818-1823.
140. Hashimoto K, Kobayashi Y, Asakura Y, et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma. 2010;51:1816-1821.
141. Kim T, Choi SH, Kim SH, et al. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Ann Hematol. 2013;92:231-238.
142. Kurokawa T, Kaya H, Yoshida T. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematop. 2010;50:159-162.
143. Lanini S, Molloy AC, Prentice AG, Ippolito G, Kibbler CC. Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study. BMC Infect Dis. 2013;13:317.
144. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14:304-313.
145. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol. 2011;6:2894-2900.
146. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant. 2010;10:89-98.
147. Scemla A, Loupy A, Candon S, et al. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation. 2010;90:1180-1184.
148. Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int. 2009;22:906-913.
149. Egawa H, Teramukai S, Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant. 2014;14:102-114.
150. Tsai MJ, Chou CW, Lin FC, Chang SC. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus. 2012;21:914-918.
151. Bonilla-Abadía F, Betancurt JF, Pineda JC, Vélez JD, Tobón GJ, Cañas CA. Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy. Clin Rheumatol. 2014;33:415-418.
152. Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults’ warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009;84:153-157.
153. Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol. 2012;90:e154-e155.
154. Kumar N, Bazari F, Rhodes A, Chua F, Tinwell B. Chronic Pneumocystis jiroveci presenting as asymptomatic granulomatous pulmonary nodules in lymphoma. J Infect. 2011;62:484-486.
155. Perez-Ordoño L, Hoyo I, Sanclemente G, et al. Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients. Transpl Infect Dis. 2014;16:324-328.
156. Kumar D, Gourishankar S, Mueller T, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis. 2009;11:167-170.
157. Chang H, Shih LY, Wang CW, Chuang WY, Chen CC. Granulomatous Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Acta Haematol. 2010;123:30-33.
158. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology. 2009;14:696-699.
159. Chang H, Yeh HC, Su YC, Lee MH. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. J Chin Med Assoc. 2008;71:579-582.
160. Jiang XQ, Fang L, Mei XD, Wang XJ, Bao MH. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review. J Thorac Dis. 2013;5:E162-E166.
161. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Schölmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 2008;47:1256-1257.
162. Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100-104.
163. van der Velden WJ, Blijlevens NM, Klont RR, Donnelly JP, Verweij PE. Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol. 2006;85:621-623.
164. Streif W, Escuriola Ettingshausen C, Linde R, Kropshofer G, Zimmerhackl LB, Kreuz W. Inhibitor treatment by rituximab in congenital haemophilia A—Two case reports. Hamostaseologie. 2009;29:151-154.
165. Li BL, Li SX, Wang TM, et al. Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:99-105.
166. Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol. 2007;86:225-226.
167. Ettahar N, Legout L, Ajana F, et al. Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab. J Mycol Med. 2013;23:57-63.
168. Marchand T, Revest M, Tattevin P, et al. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:643-645.
169. Wingfield T, Jani M, Krutikov M, et al. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford). 2011;50:1725-1727.
170. Hirai Y, Ainoda Y, Shoji T, et al. Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. Mycopathologia. 2011;172:227-232.
171. Quillet-Dye C, Meniane JC, Quist D, Desbois N. Triple cutaneous mycosis (Cunninghamella bertholletiae, Phomopsis spp. and Paraconiothyrium spp.) in an immonucompromised patient: Martinican case report. J Mycol Med. 2012;22:357-361.
172. Sanz-Bueno J, Castellanos-González M, Rodríguez-Peralto JL, Rivera R. Disseminated zygomycosis in a patient with chronic lymphocytic leukemia. Med Clin (Barc). 2013;140:e21.
173. Bakr A, Wafa E, Fouda A, et al. Successful treatment of mucormycosis in a renal allograft recipient. Clin Exp Nephrol. 2008;12:207-210.
174. Saitoh T, Matsushima T, Shimizu H, et al. Successful treatment of azole-refractory Candida guilliermondii fungemia with a combination therapy of micafungin and liposomal amphotericin B. Rinsho Ketsueki. 2008;49:94-98.
175. Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed. 2006;77:32-35.
176. Chan JF, Chan TS, Gill H, et al. Disseminated infections with Talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. 2015;21:1101-1106.
177. Hemmaway C, Laverse E, Nicholas M, Nagy Z. Cerebellar Cladophialophora bantiana infection in a patient with marginal zone lymphoma treated with immunochemotherapy including rituximab. Br J Haematol. 2011;154:423.
178. Kavcic M, Fisher BT, Seif AE, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr. 2013;162:1252-1258, 1258.e1.
179. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken). 2010;62:1661-1664.
180. Czarniak P, Załuska-Leśniewska I, Zagożdżon I, Zurowska A. Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2013;28:987-988.
181. Sato M, Ito S, Ogura M, et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:145-149.
182. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269-1279.
183. Okada N, Sanada Y, Hirata Y, et al. The impact of rituximab in ABO-incompatible pediatric living donor liver transplantation: the experience of a single center. Pediatr Transplant. 2015;19:279-286.
184. Ale'ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int. 2014;34:529-533.
185. Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J. Rituximab therapy for severe pediatric systemic lupus erythematosus. Zhonghua Er Ke Za Zhi. 2012;50:697-704.
186. Reis J, Aguiar F, Brito I. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases. Acta Reumatol Port. 2016;41:45-55.
187. Kiss F, Buslig J, Szegedi I, Scholtz B, Kappelmayer J, Kiss C. Early relapse after rituximab chemoimmunotherapy. Pediatr Blood Cancer. 2008;50:372-375.
188. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002;4:1006-1008.
189. Ng PC, Lee KK, Lo AF, Li CK, Fok TF. Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child. 2003;88:337-339.
190. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150.
191. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol. 2014;51:114-118.
192. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511-1513.
193. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-3861.
194. Ansari S, Tashvighi M, Darbandi B, Salimi AB, Golpaygani M. Rituximab for child with chronic relapsing autoimmune hemolytic anemia. Pediatr Hematol Oncol. 2011;28:164-166.
195. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50:822-825.
196. Shamriz O, Vilk SR, Wolf DG, et al. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders. Clin Immunol. 2014;151:79-83.
197. Soliris. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf. Accessed October 28, 2016.
198. Kineret. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf. Accessed October 28, 2016.
199. Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev. 2015;14:1-9.
200. Ilaris. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf. Accessed October 28, 2016.
201. Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486-2496.
202. Tysabri. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. Accessed October 28, 2016.
203. Entyvio. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf. Accessed October 28, 2016.
204. Moćko P, Kawalec P, Smela-Lipińska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Arch Med Sci. 2016;12:1088-1096.
205. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol. 2016. DOI: 10.1111/bjd.15015 [Epub ahead of print]
206. Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016;6:111-124.
207. Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb). 2014;4:1-9.
208. Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014;66:1693-1704.
209. Genovese MC, Braun DK, Erickson JS, et al. Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a Phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol. 2016;43:289-297.
210. Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1148-1155.
211. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328.
212. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594-603.
213. RoActemra. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed October 28, 2016.
214. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:R141.
215. Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012;22:122-127.
216. van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015;6:30408-30419.
217. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616-1625.
218. Rovin BH, van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68:2174-2183.
219. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.
220. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253-261.
221. Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133-1138.
222. Xolair. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf. Accessed June 12, 2016.
223. Synagis. Summary of product characteristics. European Medicines Agency (EMEA). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000257/WC500056908.pdf. Accessed June 12, 2016.
224. Evans MO 2nd, Morris MJ, Coop CA, Evans SE. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol. 2015;115:250-251.
225. Groll AH, Ritter J, Müller FM. Guidelines for prevention of Pneumocystis carinii pneumonitis in children and adolescents with cancer. Klin Padiatr. 2001;213(Suppl 1):A38-A49.
226. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397-2404.
227. Alexander BD, Fishman JA. Prophylaxis of infections in solid organ transplantation. UpToDate®. Wolters Kluwer. https://www.uptodate.com/contents/prophylaxis-of-infections-in-solid-organ-transplantation. Accessed October 28, 2016.
228. Le Saux N. Biologic response modifiers to decrease inflammation: focus on infection risks. Paediatr Child Health. 2012;17:147-154.
229. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008;126:13-30.
230. Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics. 2015;9:1-6.
231. Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-α inhibitors. J Pediatr Gastroenterol Nutr. 2016;63:130-155.